Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., June 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Conference call and webcast of the presentation of interim results from Aastrom's U.S. Phase 2b RESTORE-CLI clinical trial which will be presented at the Vascular
Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress Ann Arbor, Michigan, May 3, 2010 (3:20 pm ET) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following webcast: What: Investor conference call to present an update
ANN ARBOR, Mich., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
ANN ARBOR, Mich., Oct. 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences,
ANN ARBOR, Mich., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom will present data from an interim analysis of its Phase 2b RESTORE-CLI clinical trial at a VEITHsymposium™ non-CME satellite session. This event will include
ANN ARBOR, Mich., May 31, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the following webcast: What: Aastrom Biosciences,
ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast: What: Aastrom Biosciences, Inc.,
Campaign Aims to Empower Patients with Knee Pain to Seek Treatment CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that world champion swimmer,
